Navigation Links
CDC Awards NATT Funding to Improve Blood Clot Awareness
Date:9/26/2007

TARRYTOWN, N.Y., Sept. 26 /PRNewswire-USNewswire/ -- The National Alliance for Thrombosis and Thrombophilia (NATT) today announced the award of two major program grants totaling $1.35 million that will serve as building blocks for its efforts to curb the unchecked devastating effects caused each year to nearly one million Americans who develop a blood clot.

NATT will use its two Centers for Disease Control and Prevention (CDC) grants to "launch a national wake-up call to promote public and healthcare professional awareness of this serious medical condition that each year kills nearly 300,000 Americans," explains NATT President Randy Fenninger.

"We have a national crisis because few people recognize or understand the symptoms and risk factors of this silent killer. And even equally startling, is that not enough of our nation's healthcare professionals have a full understanding of the symptoms and the methods for treatment of this life- threatening condition," he said. Complications from clotting, occurring in more than half of those affected individuals, can often have serious consequences - as is evident from an annual mortality rate that is greater than the combined deaths from breast cancer, AIDS, and automobile accidents.

Mr. Fenninger complimented the proactive efforts of the CDC for recognizing the need to fund an all-out public and professional attack against blood clotting disorders. The awards, he notes, "serve to further support our national education and awareness work. This is a superb news for all Americans at risk for blood clots, and a very proud moment for the many volunteers who have worked so hard to move NATT from a board room dream to a now nationally respected community-based advocacy organization that does so much good."

Aiding the CDC's proactive funding efforts was a meeting held in May of 2006 by the U.S. Surgeon General who brought together national healthcare and public leaders to discuss the serious problems surrounding blood clots and clotting disorders. The general theme from this meeting is the publication of "Call-to-Action" this fall by the U.S. Surgeon General to improve education and awareness within the healthcare profession, as well as the general public.

These facts, combined with a serious lack of awareness among the public, constitute a significant public health problem that NATT has been battling since its inception in 2003. NATT Executive Director Alan Brownstein explained that a national initiative called "Stop-The-Clot," will now be launched. The multi-tiered program, one of two receiving funding awards from the CDC, will focus its education and awareness efforts on such objectives as:

-- Enhancement of NATT's successful patient seminars into a nationally

Stop-The-Clot Forum series

-- Establishment of a comprehensive consumer Clotting Information Resource

Center (CIRC; available via web and print mediums)

-- Collaboration with the national Hemophilia Treatment Centers, the

Thrombosis and Hemostasis Centers, and the Anticoagulation Forum

network for distribution of education materials

-- And the development of a regional chapter infrastructure.

The CDC also awarded funding for a nurses and non-physician healthcare professionals' education project that will specifically address the areas of blood clot prevention, diagnosis, treatment and management. NATT's Medical And Scientific Advisory Board (MASAB) Chairman Dr. Stephan Moll, director of the University of North Carolina - Chapel Hill Thrombophilia Program, expressed his board's delight regarding the CDC awards. "I commend the CDC on their efforts to respond to this extreme health issue in such a proactive manner through funding these programs instituted by NATT," he said.

Dr. Moll noted that the healthcare professionals' education project is deemed an essential element in the fight against blood clots. "Improving the content and delivery of health information/education by nurses and other non- physicians," he said, "provides an educational and training aspect to a critical part of a patient's healthcare and wellness."

The program, Dr. Moll explained, will be delivered nationally through the utilization of evidence-based teaching methods in small group sessions led by trained faculty. The program's ultimate goal is to prevent secondary conditions in people with clotting disorders by improving their access to knowledgeable healthcare providers.

NATT will collaborate with many organizations in its development of a 12- region training program. Patients will be reached throughout the U.S. network of the 140-federally funded Hemophilia Treatment Centers, the CDC Pilot Thrombophilia Centers and through participants of the Anticoagulation Forum.

(For More Information regarding the National Alliance for Thrombosis and Thrombophilia and/or their national programs, please contact Alan Brownstein at (917) 209-2000, apbrownstein@msn.com, or NATT President Randy Fenninger (202) 833-0007, or log on to http://www.nattinfo.org. NATT is a 501c3 national volunteer community-based organization, which welcomes support through involvement and/or donations. Further information can also be obtained from NATT's Medical and Scientific Advisory Board chairman Dr. Stephan Moll, University of North Carolina at Chapel Hill at (919) 966-3311 or smoll@med.unc.edu.)


'/>"/>
SOURCE National Alliance for Thrombosis and Thrombophilia
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Berbee wins two Microsoft awards
2. UWM announces winners of RGI awards
3. Madison company cosponsors young entrepreneur awards
4. Tech awards keynoter asks for support of UWM transformation
5. SBC Foundation awards technology grants in Wisconsin
6. Entries sought for New Products Awards
7. StrandVision, Arctic Cool win Eau Claire business contest awards
8. State awards QRG Biosciences development grant
9. Wisconsin Development Fund awards announced
10. NSF awards Lucigen $250,000
11. Firstlogic a finalist in DM Reviews World Class Solution Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced today the promotion of two long-standing principal investigators (PI) to the roles ... Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research PI in ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Aware, Inc. (NASDAQ: AWRE ), ... results for its fourth quarter and year ended December 31, 2015.  ... the fourth quarter of 2015 was $6.9 million, an increase of ... Operating income in the fourth quarter of 2015 was $2.6 million ... --> --> Higher revenue and ...
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/4/2016)... 4, 2016 The field of Human ... the most popular hubs of the biotechnology industry. ... huge studies of human microbiota, have garnered a ... the microbiome space has literally exploded in terms ... This report focuses on biomedical aspects of research, ...
Breaking Biology News(10 mins):